Enliven Therapeutics, Inc.
corporate_fare Company Profile
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ELVN at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Enliven Therapeutics Appoints Biopharma Veteran Scott Garland to Board, Bolstering Commercialization Expertise for Phase 3
Financial Snapshot
Fiscal year ended December 31, 2025
Net Income
-$103.69M
Diluted EPS
-$1.83
Op. Cash Flow
-$70.3M
Free Cash Flow
-$70.46M
Operating Income
-$119.66M
Cash & Equivalents
$98.9M
Debt / Equity
0.00×
Shares Outstanding
59.44M sh
Source: 10-K · filed 2026-03-03 · accession 0001193125-26-088232
show_chartPrice Chart
Loading chart...
feed ELVN - Filings & News (Page 2)
ELVN
Jan 07, 2026, 9:15 AM EST
Price at Filing:
$15.14
Real-time Price:
$46.53
Change:
+$31.39 (+207%)
Market Cap:
$3.424B